 To compare efficacy and safety of dapagliflozin Â± saxagliptin with glimepiride as add-on to metformin in patients with type 2 diabetes. This 52-week, multicenter, double-blind, active-controlled study ( NCT02471404<ORGANIZATION> ) randomized ( 1:1:1 ) patients ( n=939 ; HbA Baseline<ORGANIZATION> mean age, diabetes duration and HbA Dapagliflozin<ORGANIZATION>, saxagliptin and metformin improved glycemic control compared with glimepiride plus metformin ; add-on of dapagliflozin alone showed similar efficacy to glimepiride. Both dapagliflozin regimens decreased body weight and SBP<ORGANIZATION>, with lower hypoglycemia incidence compared with glimepiride. This article is protected by copyright. All rights reserved.